Large-scale testing (Phase 3)Active Not RecruitingNCT04639180
What this trial is testing
Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Who this might be right for
Hepatocellular Carcinoma (HCC)
Jiangsu HengRui Medicine Co., Ltd. 687